The Life Sciences team advised Isomorphic Labs on its strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.
Under the terms of the agreement, Isomorphic Labs will receive an upfront payment of $37.5 million from Novartis, in addition to Novartis funding of select research costs. Isomorphic Labs is eligible to receive up to $1.2 billion in performance-based milestone payments, excluding the upfront payment and any subsequent tiered royalties from mid-single up to low double-digit royalties on net sales.
Isomorphic Labs is a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence and an autonomous subsidiary of Alphabet that was launched from Alphabet’s DeepMind in 2021 to build on the success of AlphaFold, the company’s groundbreaking work in protein folding.
The Goodwin team was led by Noelle Dubiansky, Frank Qin and Kingsley Taft, with invaluable assistance from Daniel Karelitz, Susan Lee and Katerina Stavrianidis.
For more details, read the press release and coverage in Endpoint News, Fierce Biotech and TechCrunch.